Ignite Creation Date:
2025-12-25 @ 1:47 AM
Ignite Modification Date:
2025-12-26 @ 6:42 PM
Study NCT ID:
NCT06001294
Status:
UNKNOWN
Last Update Posted:
2023-08-22
First Post:
2023-08-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
Sponsor:
Xiangcheng Zhang
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-03
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-14
First Submit QC Date:
None
Study First Post Date:
2023-08-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-19
Last Update Post Date:
2023-08-22
Last Update Post Date Type:
ACTUAL